Table 2
Open in new tab

Follow-up clinical and imaging data of the entire study population and stratified according to the presence of HALT

All patients (131)Without HALT (105)With HALT (10)P
Echocardiography
6-month aortic Vmax (m/s)2.0 ± 0.52.0 ± 0.51.9 ± 0.50.58
(129)(103)(10)
6-month AMG (mmHg)8.5 ± 5.58.5 ± 5.88.7 ± 4.60.93
(129)(103)(10)
6-Month brain MRI
New SCIL on 6-month MRI (n; %)19/118 (16)15/93 (16)1/10 (10)0.99
6-month new SCIL volume [mm3, median (IQR)]0 (0; 0)0 (0; 0)0 (0; 0)0.71
6-month new SCIL volume (mm3, mean ± SD)17 ± 6819 ± 712 ± 50.71
New WMH on the 6-month MRI (n; %)57/87 (66)43/69 (62)8/8 (100)0.047
6-month new WMH volume [mm3, median (IQR)]58 (0; 322)50 (0; 312)319 (72; 1656)0.039
Neurocognitive outcomes
TIA/stroke/systemic embolization (n; %)2a/131 (2)2/106 (2)0/10 (0)0.99
Pre-TAVI ACE score72.2 ± 12.373.2 ± 12.678.8 ± 12.70.40
(106)(71)(5)
6-month ACE score73.7 ± 12.974.6 ± 12.475.8 ± 15.60.84
(93)(76)(5)
6-month ΔACE1.3 ± 8.51.0 ± 8.5−3.5 ± 6.40.46
(73)(61)(2)
All patients (131)Without HALT (105)With HALT (10)P
Echocardiography
6-month aortic Vmax (m/s)2.0 ± 0.52.0 ± 0.51.9 ± 0.50.58
(129)(103)(10)
6-month AMG (mmHg)8.5 ± 5.58.5 ± 5.88.7 ± 4.60.93
(129)(103)(10)
6-Month brain MRI
New SCIL on 6-month MRI (n; %)19/118 (16)15/93 (16)1/10 (10)0.99
6-month new SCIL volume [mm3, median (IQR)]0 (0; 0)0 (0; 0)0 (0; 0)0.71
6-month new SCIL volume (mm3, mean ± SD)17 ± 6819 ± 712 ± 50.71
New WMH on the 6-month MRI (n; %)57/87 (66)43/69 (62)8/8 (100)0.047
6-month new WMH volume [mm3, median (IQR)]58 (0; 322)50 (0; 312)319 (72; 1656)0.039
Neurocognitive outcomes
TIA/stroke/systemic embolization (n; %)2a/131 (2)2/106 (2)0/10 (0)0.99
Pre-TAVI ACE score72.2 ± 12.373.2 ± 12.678.8 ± 12.70.40
(106)(71)(5)
6-month ACE score73.7 ± 12.974.6 ± 12.475.8 ± 15.60.84
(93)(76)(5)
6-month ΔACE1.3 ± 8.51.0 ± 8.5−3.5 ± 6.40.46
(73)(61)(2)
a

TIA in both cases. AMG, aortic mean gradient; SCIL, silent cerebral ischaemic lesion; WMH, white matter hyperintensity; ACE, Addenbrookes Cognitive Examination; TIA, transient ischaemic attack; 6-month ΔACE, ACE score change between pre-TAVI and 6 months. 6-Month new WMH volume is presented as median values, followed by interquartile ranges in brackets, as well as mean value and standard deviation. As Table 2 is to present the consequences of HALT, patients who were HALT positive at the time of the 6-month follow-up are included in the HALT group (i.e. the two patients with acute valve thrombosis are not included in these analyses). Numbers in brackets indicate the number of patients with available data.

Table 2
Open in new tab

Follow-up clinical and imaging data of the entire study population and stratified according to the presence of HALT

All patients (131)Without HALT (105)With HALT (10)P
Echocardiography
6-month aortic Vmax (m/s)2.0 ± 0.52.0 ± 0.51.9 ± 0.50.58
(129)(103)(10)
6-month AMG (mmHg)8.5 ± 5.58.5 ± 5.88.7 ± 4.60.93
(129)(103)(10)
6-Month brain MRI
New SCIL on 6-month MRI (n; %)19/118 (16)15/93 (16)1/10 (10)0.99
6-month new SCIL volume [mm3, median (IQR)]0 (0; 0)0 (0; 0)0 (0; 0)0.71
6-month new SCIL volume (mm3, mean ± SD)17 ± 6819 ± 712 ± 50.71
New WMH on the 6-month MRI (n; %)57/87 (66)43/69 (62)8/8 (100)0.047
6-month new WMH volume [mm3, median (IQR)]58 (0; 322)50 (0; 312)319 (72; 1656)0.039
Neurocognitive outcomes
TIA/stroke/systemic embolization (n; %)2a/131 (2)2/106 (2)0/10 (0)0.99
Pre-TAVI ACE score72.2 ± 12.373.2 ± 12.678.8 ± 12.70.40
(106)(71)(5)
6-month ACE score73.7 ± 12.974.6 ± 12.475.8 ± 15.60.84
(93)(76)(5)
6-month ΔACE1.3 ± 8.51.0 ± 8.5−3.5 ± 6.40.46
(73)(61)(2)
All patients (131)Without HALT (105)With HALT (10)P
Echocardiography
6-month aortic Vmax (m/s)2.0 ± 0.52.0 ± 0.51.9 ± 0.50.58
(129)(103)(10)
6-month AMG (mmHg)8.5 ± 5.58.5 ± 5.88.7 ± 4.60.93
(129)(103)(10)
6-Month brain MRI
New SCIL on 6-month MRI (n; %)19/118 (16)15/93 (16)1/10 (10)0.99
6-month new SCIL volume [mm3, median (IQR)]0 (0; 0)0 (0; 0)0 (0; 0)0.71
6-month new SCIL volume (mm3, mean ± SD)17 ± 6819 ± 712 ± 50.71
New WMH on the 6-month MRI (n; %)57/87 (66)43/69 (62)8/8 (100)0.047
6-month new WMH volume [mm3, median (IQR)]58 (0; 322)50 (0; 312)319 (72; 1656)0.039
Neurocognitive outcomes
TIA/stroke/systemic embolization (n; %)2a/131 (2)2/106 (2)0/10 (0)0.99
Pre-TAVI ACE score72.2 ± 12.373.2 ± 12.678.8 ± 12.70.40
(106)(71)(5)
6-month ACE score73.7 ± 12.974.6 ± 12.475.8 ± 15.60.84
(93)(76)(5)
6-month ΔACE1.3 ± 8.51.0 ± 8.5−3.5 ± 6.40.46
(73)(61)(2)
a

TIA in both cases. AMG, aortic mean gradient; SCIL, silent cerebral ischaemic lesion; WMH, white matter hyperintensity; ACE, Addenbrookes Cognitive Examination; TIA, transient ischaemic attack; 6-month ΔACE, ACE score change between pre-TAVI and 6 months. 6-Month new WMH volume is presented as median values, followed by interquartile ranges in brackets, as well as mean value and standard deviation. As Table 2 is to present the consequences of HALT, patients who were HALT positive at the time of the 6-month follow-up are included in the HALT group (i.e. the two patients with acute valve thrombosis are not included in these analyses). Numbers in brackets indicate the number of patients with available data.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close